EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.
Recruiting now · Phase 1/Phase 2
Conditions studied: Non-Small Cell Lung Cancer
In brief
As treatment options are limited following progression on anti PD-(L)1 and platinum-based chemotherapy, we propose this trial for patients who have failed to respond or have shown intolerance to standard therapies or for whom no appropriate therapies are known to provide clinical benefit. Considering the strong therapeutic rationale of an association between antineoplastic immunotherapy and EXL01 (single-strain of F. prausnitzii, a bacteria which is a dominant member of the healthy gut microbiota), we propose to assess this combination for NSCLC treatment. This is a pilot, Phase I/II, one-arm, monocentric study evaluating the combination of EXL01 with nivolumab treatment for Non-Small Cell Lung Cancer patients.
Key facts
- Study ID
- NCT06448572
- Run by
- University Hospital, Lille
- People needed
- 21
- Starts
- 2024-07-16
- Expected to finish
- 2028-10-01
- Last updated by the study team
- 2025-09-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CHU Lille — Lille, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.